Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
94
Not yet recruiting, industry sponsors, Cardiovascular and metabolic, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting187
- Completed2,126
94 trials
Showing 1 to 25, recently updated first.
- A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or ObesityNot yet recruiting
Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
NCT07950462 · 40 participants (planned) · Start Jan 13, 2027 · Primary completion Oct 29, 2027
Drug: QLS7402 Injection; Placebo control · For: Overweight or Obesity
- A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular RiskPivotal-lookingNot yet recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07946783 · 103 participants (planned) · Start Nov 19, 2026 · Primary completion Sep 30, 2027
Drug: Single-ascending Dose (SAD) study and Food Effect (FE) study; Multiple-ascending Doses (MAD) study and 1 more · For: Obesity With Cardiovascular Risk Study
Sites: Melbourne, Australia
- Safety and Drug Concentrations of REGN20566 in Adults With Overweight or ObesityPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07947966 · 304 participants (planned) · Start Dec 14, 2026 · Primary completion Feb 2, 2028
Drug: REGN20566; Placebo · For: Overweight; Obesity
- A Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy ParticipantsNot yet recruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07922798 · 60 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 29, 2026
Drug: UBT48128; Placebo · For: Overweight , Obesity
Sites: Changsha, China
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07944118 · 36 participants (planned) · Start Nov 12, 2026 · Primary completion Jan 14, 2028
Drug: Zenagamtide · For: Overweight; Obesity; Type 2 Diabetes
Sites: Cypress, California
- A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or ObesityPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07940582 · 102 participants (planned) · Start Nov 13, 2026 · Primary completion May 29, 2028
Drug: NNC0721-5186; Semaglutide and 1 more · For: Overweight; Obesity
Sites: Cypress, California
- A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 DiabetesPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07940803 · 300 participants (planned) · Start Nov 13, 2026 · Primary completion Mar 25, 2028
Drug: NNC0662-3168 (Test product-A); Placebo matched to NNC0662-3168 (Test product-A) and 1 more · For: Overweight; Obesity; Type 2 Diabetes Mellitus
Sites: Tempe, Arizona; Lincoln, Nebraska
- A Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled HypertensionNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07940647 · 24 participants (planned) · Start Nov 23, 2026 · Primary completion Nov 5, 2027
Drug: HJB647; Placebo · For: Uncontrolled Hypertension
- A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.Pivotal-lookingNot yet recruiting
Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
NCT07937787 · 124 participants (planned) · Start Nov 20, 2026 · Primary completion Aug 30, 2027
Drug: QLS2406-1 injection; Placebo and 20 more · For: Overweight and Obesity; MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Study of IPG1094 Tablets in Chinese Healthy Adults and Obese AdultsNot yet recruiting
Nanjing Immunophage Biotech Co., LtdIndustry
NCT07935291 · 72 participants (planned) · Start Nov 25, 2026 · Primary completion Jun 25, 2027
Drug: IPG1094 Tablet and matching Placebo · For: Healthy Volunteers; Obesity
Sites: Hangzhou, China
- A Phase I Study to Evaluate the Food Effect on Ecnoglutide TabletNot yet recruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07936058 · 72 participants (planned) · Start Nov 3, 2026 · Primary completion Apr 15, 2027
Drug: Dose 1; Dose 2 · For: Food Effect in Healthy Volunteers; Weight Management
Sites: Hangzhou, China
- ARTEMIS: Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy for Acute Ischemic StrokeNot yet recruiting
Royan Stem Cell Technology CompanyIndustry
NCT07913282 · 10 participants (planned) · Start Nov 20, 2026 · Primary completion Nov 20, 2027
Drug: Allogeneic Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) · For: Acute Ischemic Stroke
Sites: Tehran, Iran
- HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass SurgeryNot yet recruiting
HELP Therapeutics, Inc.Industry
NCT07646210 · 12 participants (planned) · Start Feb 2027 · Primary completion Feb 2028
Drug: HiCM-188 Cells · For: Advanced Heart Failure; Ischemic Heart Failure
Sites: Houston, Texas
KaileraIndustry
NCT07924761 · 60 participants (planned) · Start Nov 2026 · Primary completion Apr 2027
Drug: KAI-4729 · For: Overweight or Obesity
Sites: Anaheim, California
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesPivotal-lookingNot yet recruiting
AmgenAmgen (AMGN)
NCT07921316 · 356 participants (planned) · Start Nov 9, 2026 · Primary completion Jul 26, 2027
Drug: Maridebart cafraglutide · For: Obesity; Overweight
- A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy ParticipantsNot yet recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07916194 · 24 participants (planned) · Start Nov 13, 2026 · Primary completion Jun 19, 2027
Drug: Zovaglutide; Zovaglutide and 1 more · For: Overweight, Obesity
Sites: Chongqing, China; Zhengzhou, China; Chengdu, China
- Study of AB-110 in Healthy and Hypertensive ParticipantsPivotal-lookingNot yet recruiting
Antlia Bioscience, IncIndustry
NCT07916961 · 104 participants (planned) · Start Nov 2026 · Primary completion Sep 2027
Drug: Active drug; AB-110 Matching Placebo · For: Hypertension (HTN); Healthy Adult Participants
Sites: Auckland, New Zealand
- A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Not yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911514 · 60 participants (planned) · Start Nov 9, 2026 · Primary completion May 4, 2027
Drug: AZD9550 solution for injection; AZD6234 solution for injection and 4 more · For: Healthy Participants
Sites: Ruddington, United Kingdom
- A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.Pivotal-lookingNot yet recruiting
Superluminal Medicines, Inc.Industry
NCT07905560 · 138 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: SUN-0864 or placebo; SUN-0864 or placebo and 3 more · For: Healthy Participants
- A Bioequivalence and Safety Study of AJU-C719 and C719R in Healthy Adult VolunteersNot yet recruiting
AJU Pharm Co., Ltd.Industry
NCT07901114 · 60 participants (planned) · Start Nov 2026 · Primary completion Dec 2026
Drug: Test Drug; Reference Drug · For: Hypertension
Sites: Seoul, South Korea
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 DiabetesPivotal-lookingNot yet recruiting
Paulex Bio Inc.Industry
NCT07901595 · 147 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 1, 2027
Drug: PAL-119; Placebo · For: Healthy Volunteers and Diabetes Participants
- EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Not yet recruiting
Editas Medicine, Inc.Industry
NCT07894887 · 56 participants (planned) · Start Nov 2026 · Primary completion Jun 2029
Drug: Drug: EDIT-401 · For: Heterozygous Familial Hypercholesterolemia (HeFH)
Sites: Charlestown, Australia; Perth, Australia
- A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy SituationsPivotal-lookingNot yet recruiting
Cilcare SASIndustry
NCT07472907 · 135 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: CIL001 (Paliroden); Placebo · For: Cochlear Synaptopathy
iBio, Inc.Industry
NCT07890870 · 32 participants (planned) · Start Dec 2026 · Primary completion Jan 2028
Drug: IBIO-610; Placebo · For: Obesity & Overweight
Sites: Brisbane, Australia
- Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 DiabetesNot yet recruiting
SeraxisIndustry
NCT07581197 · 9 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: Allogeneic pancreatic endocrine cell clusters · For: Diabete Mellitus; Diabete Type 1
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.